Overcoming the impact of the COVID‐19 pandemic on oncology early phase trials and drug development in Asia—Experiences and perspectives of the Asian Oncology Early Phase 1 Consortium

AIM: The significance and prioritization of early phase oncology trial continuation during a global pandemic is unknown. This study reported the outcomes, multiple challenges, and broad recommendations associated with the impact of the novel coronavirus disease 2019 (COVID‐19) on oncology early phas...

Descripción completa

Detalles Bibliográficos
Autores principales: Shimizu, Toshio, Kim, Dong‐Wan, Loong, Herbert H., Lin, Chia‐Chi, Ng, Matthew CH, Yamamoto, Noboru, Ma, Brigette, Tan, Daniel SW
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8014030/
https://www.ncbi.nlm.nih.gov/pubmed/33502085
http://dx.doi.org/10.1111/ajco.13510

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8014030/
https://www.ncbi.nlm.nih.gov/pubmed/33502085
http://dx.doi.org/10.1111/ajco.13510

Ejemplares similares